News | March 13, 2021
AstraZeneca Pharma India receives approval for supplying Osimertinib in India
The receipt of this permission paves way for the launch of Osimertinib 40mg/80mg film coated tablets in India.
The receipt of this permission paves way for the launch of Osimertinib 40mg/80mg film coated tablets in India.
Approval brings AstraZeneca and Daiichi Sankyo’s Enhertu earlier in the treatment of HR-positive, HER2-low breast cancer and broadens the eligible patient population to those with HER2-ultralow disease
Experts urge early detection & better access to care
Imfinzi reduced the risk of distant metastases and death from bladder cancer vs. neoadjuvant chemotherapy alone
The PATHWAY HER2 (4B5) test, the first and only FDA approved companion diagnostic for assessing HER2-low status since 2022, is now also approved to aid in the assessment of HER2-ultralow status for metastatic breast cancer patients.
Based on DESTINY-Breast06 Phase III trial results which showed Enhertu demonstrated superiority vs. chemotherapy with a median progression-free survival of more than one year
Datroway is the eighth new medicine of the 20 AstraZeneca has set out to deliver by 2030
Based on ECHO Phase III trial results which showed more than 16 months of progression-free survival improvement vs. chemoimmunotherapy alone
He is an experienced professional in the pharmaceutical industry with about 30 years of progressive experience
First and only PARP inhibitor to improve overall survival in early breast cancer
Subscribe To Our Newsletter & Stay Updated
